CALGARY, Dec. 7, 2016 /CNW/ - Zenith Capital Corp. ("Zenith" or the "Company") announces webcast details for a corporate update that will be presented at the Company's Annual and Special Meeting.
The Zenith Annual and Special Meeting of Shareholders will take place on Thursday, December 15, 2016 at Mount Royal University, Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate SW, Calgary, Alberta, commencing at 11:00 am (MST). A notice of meeting and management information circular, containing the matters to be considered at the meeting, is filed and available on SEDAR at www.sedar.com and on the Zenith website at this LINK.
Following the formal business of the meeting, Mr. Donald J. McCaffrey, President and Chief Executive Officer, will deliver a corporate update presentation which will be webcast.
Date: Thursday, December 15, 2016
Time: Approximately 11:30 am MST – following the formal business of the Meeting
Webcast Link: Click hear to launch the webcast viewer
The presentation will be available on the Company's website immediately prior to the start of the event. Click on this LINK to go directly to the appropriate page on the Company's website. An archived replay of the webcast will also be available on the Company website by clicking on this LINK.
Zenith Capital Corp. is a biotechnology investment company. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics. Zenith Epigenetics Ltd.'s bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well. The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer ("mCRPC").
SOURCE Zenith Capital Corp.
For further information: please contact: Clayton Paradis, Zenith Capital Corp., Phone: 587-390-7865, Email: email@example.com